NCT07272343RecruitingPhase 4
The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
A Study on the Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes Combined With Metabolic-associated Fatty Liver Disease and Its Molecular Mechanisms
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory markers, liver fat content, and other parameters. The study also observed the subcutaneous and visceral fat of the participants and explored the molecular mechanisms of action, providing high-quality evidence-based support for the timing and targets of intervention in this population.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 16 Nov 2025
- Start date
- 10 Feb 2023
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Second Affiliated Hospital of Nanchang University
- NCT number
- NCT07272343
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- From 10 Feb 2023 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of type 1 diabetes, acute pancreatitis, or diabetes secondary to pancreatectomy;
- History of bariatric surgery or planned bariatric surgery, or currently attempting weight loss within the past 3 months, or use of weight-loss medications within the past 3 months;
- Patients with severe diseases of important organ systems, such as severe cardiovascular and cerebrovascular diseases, respiratory diseases, gastrointestinal diseases, renal insufficiency, hematologic diseases, neurological diseases, or malignancies;
- Personal or family history of medullary thyroid carcinoma;
- Patients with severe mental disorders or communication barriers that prevent accurate understanding of the study content and compliance with the trial procedures.
Lab values
- Use of GLP-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, or other related drugs within the past 3 months;
Age
- Age \< 18 years, or \> 75 years;
Other
- BMI \< 25 kg/m²;
- Pregnant or breastfeeding women, or those planning to conceive during the study period;
Who the study is looking for
- Age 18-75 years;
- BMI≥25 kg/m²;
- Diagnosed as type 2 diabetes mellitus patients according to the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)";
- HbA1c≤8.5%;
- Duration of diabetes ≤3 months, and no use of antihyperglycemic drugs;
- Willing to participate in this study, and after full informed consent, agrees to strictly follow the treatment plan and promises to attend follow-up visits on time, and signs the informed consent form.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Minde road No.1 Coordinator of this site? Confirm its status | Jiangxi | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.